Namita Nabar

1 Introduction Nucleic acid therapeutics are a powerful modality to address a broad range of acute and chronic diseases. Over the past decade, gene therapies have powered significant strides in the management and treatment of diseases including cancers [1], liver conditions [2, 3], hematological disorders [4], and prophylactics against infectious diseases [5, 6].

Abstract Engineered nanoparticles have greatly expanded cancer treatment by encapsulating and delivering therapeutic and diagnostic agents, otherwise limited by poor pharmacokinetics and toxicity, to target tumour cells. Leveraging our increased understanding of the tumour microenvironment, nanomedicine has expanded to additionally target key tissues and cells implicated in tumorigenesis, such as immune and stromal cells, to improve potency and further mitigate off-target toxicities.